News & Updates

A low-carbohydrate, high-fat (LCHF) diet averts disease progression in patients with nonalcoholic fatty liver disease (NAFLD) in a new study presented at ILC 2022.

One in three hospitalized patients with cirrhosis and acute kidney injury (AKI) develop acute kidney disease (AKD), which is associated with worse survival and de novo chronic kidney disease (CKD), reveals a recent study. Interventions targeting AKD may improve outcomes of these patients.

Prediction equations appear to provide no useful estimates of resting energy expenditure (REE) in patients with cirrhosis, reports a study, adding that REE must be measured directly.

Rifaximin soluble solid dispersion immediate-release tablet has the potential to reduce hospitalization in patients with cirrhosis and promote the resolution of overt hepatic encephalopathy (OHE) during hospitalization, according to analyses of two phase II trials.

Patients with paediatric-onset autoimmune liver disease show slower early immunological and biochemical response to a tacrolimus-based treatment as compared with regimens using prednisolone or azathioprine, reports a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2022).

Liver stiffness appears to increase the likelihood of atrial fibrillation (AF), according to a recent sub-analysis of the Rotterdam Study. Fatty liver disease, on the other hand, does not affect AF risk.